Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
2623results about "Immunoglobulins against growth factors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Polypeptide variants with altered effector function
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
Owner:GENENTECH INC
Anti-PD-L1 antibodies, compositions and articles of manufacture
Owner:F HOFFMANN LA ROCHE & CO AG
Humanized anti-TGF-beta antibodies
Owner:GENENTECH INC
Multispecific antibodies
ActiveUS20080069820A1High binding affinityHigh affinityImmunoglobulins against growth factorsAntibody ingredientsSpecific antibody
Owner:GENENTECH INC
Variable domain library and uses
ActiveUS20050266000A1Generate efficientlyQuality improvementImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsComplementarity determining regionAntigen binding
The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.
Owner:GENENTECH INC
Treatment with anti-VEGF antibodies
InactiveUS20050186208A1Effective approachExtended durationBiocidePeptide/protein ingredientsAbnormal tissue growthAnti vegf antibody
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Owner:GENENTECH INC
Compositions for targeting the vasculature of solid tumors
InactiveUS6051230AEffectively compete for bindingReduce TEC-4 or TEC-11 bindingHybrid immunoglobulinsPeptide/protein ingredientsAntigenCell Surface Antigens
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Fc variants with optimized properties
InactiveUS20060235208A1Improve bindingStrong cytotoxicityImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against growth factorsChemistry
Owner:XENCOR
Fc VARIANTS WITH ALTERED BINDING TO FcRn
ActiveUS20090163699A1Extended half-lifeNervous disorderAntibody mimetics/scaffoldsWild typeChemistry
The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y / 428L, 252Y / 434S, and 428L / 434S, and the numbering is according to the EU index.
Owner:XENCOR
Anti-pd-l1 antibodies and their use to enhance t-cell function
ActiveUS20100203056A1Reduce level of pathogenChronic infectionAntibacterial agentsOrganic active ingredientsT-cell dysfunctionPD-L1
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:F HOFFMANN LA ROCHE & CO AG
Specific binding agents to hepatocyte growth factor
ActiveUS20050118643A1Readily apparentDecreasing or preventing binding of a specific binding agentPeptide/protein ingredientsImmunoglobulins against growth factorsHepatocyte growth factorCancer
Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.
Owner:AMGEN INC +1
Polypeptide variants
InactiveUS7297775B2Peptide/protein ingredientsAntibody mimetics/scaffoldsAmino acid substitutionComplement-dependent cytotoxicity
Owner:GENENTECH INC
Radioimmunotherapy of lymphoma using anti-CD20 antibodies
Owner:GLAXO SMITHKLINE LLC
Monoclonal antibodies detection methods for enzymes that confer resistance to 2,4-dichlorophenoxyacetic acid in plants
ActiveUS8460891B2Animal cellsImmunoglobulins against cytokines/lymphokines/interferonsMonoclonal antibodyDioxygenase
Owner:CORTEVA AGRISCIENCE LLC
Polypeptide variants with altered effector function
InactiveUS20060067930A1High affinity bindingWeaker binding affinityCompound screeningNervous disorderEffector functionsMolecular biology
The invention provides polypeptides having IgG Fc regions with amino acid modifications that result in the polypeptides exhibiting altered Fc effector functions.
Owner:GENENTECH INC
Bivalent, bispecific antibodies
ActiveUS20090162360A1Increase heterodimerisationIncrease productionAnimal cellsHybrid immunoglobulinsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Radioimmunotherapy of lymphoma using anti-CD20 antibodies
Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy also described is a composition useful in the treatment of lymphoma.
Owner:RGT UNIV OF MICHIGAN +2
Monoclonal antibodies to hepatocyte growth factor
InactiveUS7220410B2Animal cellsBiological material analysisMonoclonal antibodyHepatocyte growth factor
The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Owner:GALAXY BIOTECH LLC
Polypeptide variants with altered effector function
InactiveUS7183387B1Improve bindingAltered affinityAntibody mimetics/scaffoldsImmunoglobulins against growth factorsAmino acidEffector functions
Owner:GENENTECH INC
Antibodies against insulin-like growth factor 1 receptor and uses thereof
ActiveUS20050008642A1Slow tumor growthExtension of timeImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsBiologyAntibody
Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
InactiveUS7247301B2Less immunogenicReduce adverse side effectsInorganic active ingredientsImmunoglobulins against cytokines/lymphokines/interferonsV(D)J recombinationHuman epidermal growth factor receptor
Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Owner:GENMAB INC
Bivalent, bispecific antibodies
InactiveUS20090162359A1Increase productionImprove purification effectAnimal cellsHybrid immunoglobulinsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Antibody inhibitors of GDF-8 and uses thereof
ActiveUS7320789B2Reduction in one or more of the biological activitiesReduced activityNervous disorderMuscular disorderAntibody inhibitorAntibody fragments
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
Owner:WYETH LLC
Bivalent, bispecific antibodies
ActiveUS20090232811A1Increase productionImprove purification effectAnimal cellsAntibody mimetics/scaffoldsBispecific antibodySpecific antibody
Owner:F HOFFMANN LA ROCHE & CO AG
Anti-activin a antibodies and uses thereof
ActiveUS20090234106A1Loss of body weightMassive lossAntipyreticAnalgesicsNucleotideAntibody fragments
The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
Owner:AMGEN INC
Polypeptide variants with altered effector function
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
Owner:GENENTECH INC
Antibodies with modified isoelectric points
ActiveUS20120028304A1Increased serum half-lifeMinimize the possibilityAnimal cellsSugar derivativesHalf-lifeBlood plasma
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
Owner:XENCOR
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
A method for enhancing a binding activity of an antibody composition to Fcgamma receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcgamma receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.
Owner:KYOWA HAKKO KIRIN CO LTD
Anti-VEGF antibodies
ActiveUS20070020267A1Inhibit bindingSenses disorderImmunoglobulins against growth factorsAnti vegf antibodyBacteriophage
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com